University of Khartoum   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Khartoum Sudan (1902)

Organization Overview

First Clinical Trial
2004
NCT00330902
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Consultant Nephrologist | Department of physiology Faculty of Medicine Alneelain University Khartoum, | Director, Institute of Endemic Diseases, University of Khartoum Associate Professor, Head, Department of Clinical Pathology & Immunology | Faculty of Medicine, University of Khartoum | Institute of Endemic Diseases (IED), University of Khartoum | lecturer in physiology department University of Khartoum | National Center for Kidney Diseases and Surgery | The Institute of Endemic Diseases (IEND), University of Khartoum | University of Khartom , Institute of Endemic Diseases | University of Khartoum | University of Khartoum Faculty of Medicine Department of Physiology | University of Khartoum, Sudan

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abortion, Spontaneous (Phase 4)

Anemia (Phase 3)

Anemia, Sickle Cell (Phase 3)

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Infections (Phase 3)

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 2)

Leishmaniasis, Visceral (Phase 3)

Malaria (Phase 4)

Malaria, Falciparum (Phase 3)

Malaria, Vivax (Phase 3)

Parasitemia (Phase 3)

Polycystic Ovary Syndrome (Phase 2)

Pulpitis (Phase 2)

Schistosomiasis (Phase 3)

Schistosomiasis haematobia (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 28